HHS Eyes Value-Based Drug Pricing, Transparency Policies To Curb Costs

The Obama administration is considering ideas to control drug prices that include contracting with drug makers to pay prices based on performance, employing pharmaceutical cost transparency measures akin to those that some state legislatures have proposed and targeting single-source drugs for price negotiations, according to an HHS official. HHS Assistant Secretary for Planning and Evaluation Richard Frank said drug makers and others have shown interest in the pay-for-performance approach so that might be an area ripe for consideration. Frank discussed...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.